CORCEPT THERAPEUTICS INC State and Local Income Tax Expense (Benefit), Continuing Operations
CORCEPT THERAPEUTICS INC (CORT) reported State and Local Income Tax Expense (Benefit), Continuing Operations of -$2.66 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations · last filed 2026-02-24
- CORCEPT THERAPEUTICS INC state and local income tax expense (benefit), continuing operations for the quarter ending 2020-12-31 was -$3.11M, a 374.19% decline year-over-year.
- CORCEPT THERAPEUTICS INC state and local income tax expense (benefit), continuing operations for the quarter ending 2020-09-30 was $2.00M, a 4.76% decline year-over-year.
- CORCEPT THERAPEUTICS INC state and local income tax expense (benefit), continuing operations for the quarter ending 2020-06-30 was $3.00M, a 328.57% increase year-over-year.
- CORCEPT THERAPEUTICS INC state and local income tax expense (benefit), continuing operations for the quarter ending 2020-03-31 was $4.00M, a 344.44% increase year-over-year.
- CORCEPT THERAPEUTICS INC state and local income tax expense (benefit), continuing operations for fiscal 2025 was -$2.66M, a 139.53% decline from fiscal 2024.
- CORCEPT THERAPEUTICS INC state and local income tax expense (benefit), continuing operations for fiscal 2024 was $6.72M, a 35.92% increase from fiscal 2023.
- CORCEPT THERAPEUTICS INC state and local income tax expense (benefit), continuing operations for fiscal 2023 was $4.95M, a 17.68% increase from fiscal 2022.
- CORCEPT THERAPEUTICS INC state and local income tax expense (benefit), continuing operations for fiscal 2022 was $4.20M, a 33.06% increase from fiscal 2021.
| Period end | State and Local Income Tax Expense (Benefit), Continuing Operations 3 month | State and Local Income Tax Expense (Benefit), Continuing Operations 6 month | State and Local Income Tax Expense (Benefit), Continuing Operations 9 month | State and Local Income Tax Expense (Benefit), Continuing Operations 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$2.66M 10-K · filed 2026-02-24 | |||
| 2024-12-31 | $6.72M 10-K · filed 2026-02-24 | |||
| 2023-12-31 | $4.95M 10-K · filed 2026-02-24 | |||
| 2022-12-31 | $4.20M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | $3.16M 10-K · filed 2024-02-15 | |||
| 2020-12-31 | -$3.11M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$1.11M derived: sum of 2 quarters · filed 2023-02-28 | $1.89M derived: sum of 3 quarters · filed 2023-02-28 | $5.89M 10-K · filed 2023-02-28 |
| 2020-09-30 | $2.00M 10-Q · filed 2020-11-03 | $5.00M derived: sum of 2 quarters · filed 2020-11-03 | $9.00M 10-Q · filed 2020-11-03 | $10.13M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $3.00M 10-Q · filed 2020-08-04 | $7.00M 10-Q · filed 2020-08-04 | $8.13M derived: sum of 3 quarters · filed 2022-02-15 | $10.23M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $4.00M 10-Q · filed 2020-05-04 | $5.13M derived: sum of 2 quarters · filed 2022-02-15 | $7.24M derived: sum of 3 quarters · filed 2022-02-15 | $7.93M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $3.23M derived: sum of 2 quarters · filed 2022-02-15 | $3.94M derived: sum of 3 quarters · filed 2022-02-15 | $4.83M 10-K · filed 2022-02-15 |
| 2019-09-30 | $2.10M 10-Q · filed 2020-11-03 | $2.80M derived: sum of 2 quarters · filed 2020-11-03 | $3.70M 10-Q · filed 2020-11-03 | $4.00M derived: sum of 4 quarters · filed 2021-02-23 |
| 2019-06-30 | $700.00K 10-Q · filed 2020-08-04 | $1.60M 10-Q · filed 2020-08-04 | $1.90M derived: sum of 3 quarters · filed 2021-02-23 | $2.90M derived: sum of 4 quarters · filed 2021-02-23 |
| 2019-03-31 | $900.00K 10-Q · filed 2020-05-04 | $1.20M derived: sum of 2 quarters · filed 2021-02-23 | $2.20M derived: sum of 3 quarters · filed 2021-02-23 | $2.70M derived: sum of 4 quarters · filed 2021-02-23 |
| 2018-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23 | $1.30M derived: sum of 2 quarters · filed 2021-02-23 | $1.80M derived: sum of 3 quarters · filed 2021-02-23 | $2.50M 10-K · filed 2021-02-23 |
| 2018-09-30 | $1.00M 10-Q · filed 2019-11-07 | $1.50M derived: sum of 2 quarters · filed 2019-11-07 | $2.20M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $500.00K 10-Q · filed 2019-08-01 | $1.20M 10-Q · filed 2019-08-01 | ||
| 2018-03-31 | $600.00K 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | -$4.48M 10-K · filed 2020-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |